The Q4 2026 clinical data readout for APR-1051 is the primary near-term catalyst. Monitor for enrollment updates and any early efficacy signals that could de-risk the program. The current cash runway provides a long development horizon, reducing near-term financing risk.
Price Chart
Executive Summary
Aprea Therapeutics reported Q2 2026 financial results with a net loss of $3.6M ($-0.07/share), widening from a $3.2M loss in Q2 2025, driven by increased R&D spending on the lead WEE1 inhibitor APR-1051. The company highlighted accelerating enrollment in the Phase 1 ACESOT-1051 trial, with a next clinical data update expected in Q4 2026, and maintained a cash runway into Q1 2028. The $8M market cap stock is a pre-revenue clinical-stage biotech, making the EPS miss a mechanical artifact of share count changes rather than a fundamental deterioration, while the pipeline progress provides a modest positive catalyst.
Key Financial Metrics
Key Facts
- Net loss of $3.6M in Q2 2026 vs $3.2M in Q2 2025.
- EPS of $(0.07) on 53.5M shares vs $(0.53) on 6.1M shares in Q2 2025.
- Cash and equivalents of $41.2M as of June 30, 2026, with runway into Q1 2028.
- Enrollment in the Phase 1 ACESOT-1051 trial of APR-1051 is accelerating, with sites expanding from 3 to 10.
- Next clinical data update from ACESOT-1051 expected in Q4 2026.
- R&D expenses increased to $2.5M from $1.9M, driven by higher costs for the APR-1051 trial.
- Operating loss widened to $4.0M from $3.4M in the prior year quarter.
Financial Impact
Net loss increased by $0.4M year-over-year to $3.6M; cash burn rate is approximately $2M per month based on cash balance decline from $46.5M (March 31) to $41.2M (June 30).
Risk Factors
- Clinical trial failure or disappointing efficacy/safety data for APR-1051.
- Dilution risk from the large warrant overhang (89.4M warrants vs 12.6M common shares outstanding).
- Pre-revenue status with no approved products and no guarantee of future regulatory approval.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-094542 |
| Document: apre-20260812xex99d2.htm | 0001104659-26-094542 |
| Document: apre-20260812x8k.htm | 0001104659-26-094542 |
| Document: 0001104659-26-094542-index-headers.html | 0001104659-26-094542 |
| Document: 0001104659-26-094542-index.html | 0001104659-26-094542 |
| Document: 0001104659-26-094542.txt | 0001104659-26-094542 |
| 8-K Data (Synthetic) | 0001104659-26-094542 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 28, 2026 8w ago | 8-K | $0.8386 | awaiting T+60 | — | $0.5180 (−38.23%) |
Aug 12, 2026 10w ago | 8-K | $0.6830 | awaiting T+60 | — | $0.5180 (−24.16%) |
Aug 12, 2026 10w ago | Press Release | $0.6830 | awaiting T+60 | — | $0.5180 (−24.16%) |
May 13, 2026 23w ago | 8-K | $0.8800 $0.6503 | ▼ −26.10% | ▼ −30.54% | $0.5180 (−41.14%) |
May 13, 2026 23w ago | Press Release | $0.8800 $0.6503 | ▼ −26.10% | ▼ −30.54% | $0.5180 (−41.14%) |
Apr 30, 2026 25w ago | DEFA14A | $0.8000 $0.6247 | ▲ +21.91% | ▲ +25.02% | $0.5180 (+35.25%) |
Apr 22, 2026 26w ago | S-3 | $0.8840 $0.6690 | ▲ +24.32% | ▲ +29.34% | $0.5180 (+41.40%) |
Apr 21, 2026 26w ago | Press Release | $0.9070 $0.6900 | ▼ −23.93% | ▼ −30.82% | $0.5180 (−42.89%) |
Mar 31, 2026 29w ago | Insider Cluster | $0.7630 $0.7900 | ▲ +3.54% | ▼ −8.84% | $0.5180 (−32.11%) |
Mar 20, 2026 31w ago | EFFECT | $0.7620 $0.6990 | ▼ −8.27% | ▼ −22.69% | $0.5180 (−32.02%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers